Prosecution Insights
Last updated: April 19, 2026
Application No. 17/431,740

A METHOD AND COMPOSITION FOR INSECT REPELLENCY USING AVERSIVE AGENT

Non-Final OA §103
Filed
Aug 18, 2021
Examiner
SEITZ, ANTHONY JOSEPH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UPL Corporation Limited
OA Round
6 (Non-Final)
68%
Grant Probability
Favorable
6-7
OA Rounds
3y 8m
To Grant
96%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
108 granted / 158 resolved
+8.4% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
74 currently pending
Career history
232
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
25.8%
-14.2% vs TC avg
§102
18.7%
-21.3% vs TC avg
§112
23.2%
-16.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 158 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Request for Continued Examination A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 26th 2026 has been entered. DETAILED ACTION Status of the Claims Claims 1, 3, and 6-9 are pending and are examined on their merits. 35 U.S.C. § 103 Rejections Overcome by Amendment Applicant’s amendments in the response filed on January 26th 2026 are acknowledged. Applicant has amended the claims to be directed towards a granular formulation of the composition. As neither Long nor Tortillard provide any suggestion of solid/granulated formulations, the amendments have overcome the previous 103 rejections of the claims and said rejections are thereby withdrawn. Duplicate Claims Applicant is advised that should claim 1 be found allowable, claim 6 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). 35 U.S.C. § 103 Rejections Necessitated by Amendment In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 3, and 6-9 are rejected under 35 U.S.C. 103 as being unpatentable over Messina (U.S. Patent No. 9,572,348 issued on February 21st 2017) in view of Long (GB2213724A published on August 23rd 1989), EFSA (European Food Safety Authority (EFSA); Brancato et al., Review of the existing maximum residue levels for denathonium benzoate according to Article 12 of Regulation (EC) No 396/2005. EFSA J. 2018 Mar 22;16(3):e05232), and Blum (U.S. Patent No. 5,891,919 issued on April 6th 1999). Claims 1, 3, and 6-9 are directed towards an insect-repellent composition (see claims 1, 7, 8, 9) comprising: 0.01 – 25 % denatonium benzoate (see claims 1, 3, 6, 7, 9) 1 – 25 % of a carrier selected from sodium lauryl sulfate, polyvinyl acetate, polyvinyl pyridine, polyvinyl pyrrolidone, styrene acrylic, alkoxylates, kaolin clay, clove, cinnamon, cator oil, peppermint, garlic, and walnut shells (see claims 1, 7, 8) In a granular formulation (See claims 1, 7, 8) Messina teaches the following composition: PNG media_image1.png 175 299 media_image1.png Greyscale (Messina, col. 16). As each of Messina’s Mint oil, Castor oil, and Cinnamon oil concentration ranges carry significant overlap with applicant’s 1-25% range, one of ordinary skill in the art would consider applicant’s carrier concentration ranges to be prima facie obvious (See MPEP 2144.05(I)). Messina further teaches denatonium benzoate as one of the “other ingredients” (Messina, col. 17). Messina does not teach a particular concentration for the denatonium benzoate, but one of ordinary skill in the art would have a reasonable expectation of success in developing a composition wherein the denatonium benzoate concentration is within applicant’s range of 0.01% to 25%, because such a range encompasses the typical concentrations of denatonium compounds used in repellent compositions. For example, see: Long, who teaches a repellent composition with a denatonium benzoate concentration of 0.125 g/L (0.0125 wt%) (Long, claim 4) EFSA, who describes the application of a 0.11 g/L (0.011 wt%) denatonium benzoate composition (EFSA, pg. 9) Blum teaches a concentration of 0.01 to 15% denatonium capsaicinate in repellent compositions (Blum, col. 4). One of ordinary skill in the art developing a repellent composition similar to Messina’s, comprising denatonium benzoate would therefore have a reasonable expectation of success in optimizing the denatonium benzoate concentration to the range of 0.01-25%, a concentration range well-supported in the art for denatonium compounds in repellent compositions, and the described denatonium concentration range is therefore prima facie obvious. Regarding the granular formulation, Messina teaches that the above composition can be in a granular form (Messina, col. 17). As each of the limitations of claims 1, 3, and 6-9 are obvious, claims 1, 3, and 6-9 are therefore prima facie obvious. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anthony Seitz whose telephone number is (703)756-4657. The examiner can normally be reached 7:30 AM ET - 5:00 PM ET M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.J.S./Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Aug 18, 2021
Application Filed
May 13, 2024
Non-Final Rejection — §103
Aug 26, 2024
Response Filed
Aug 28, 2024
Final Rejection — §103
Nov 08, 2024
Response after Non-Final Action
Jan 10, 2025
Request for Continued Examination
Jan 15, 2025
Response after Non-Final Action
Feb 14, 2025
Final Rejection — §103
Apr 21, 2025
Response after Non-Final Action
May 19, 2025
Request for Continued Examination
May 20, 2025
Response after Non-Final Action
Jun 10, 2025
Non-Final Rejection — §103
Sep 02, 2025
Response Filed
Sep 16, 2025
Final Rejection — §103
Nov 24, 2025
Response after Non-Final Action
Dec 30, 2025
Interview Requested
Jan 08, 2026
Examiner Interview Summary
Jan 08, 2026
Applicant Interview (Telephonic)
Jan 26, 2026
Request for Continued Examination
Jan 28, 2026
Response after Non-Final Action
Apr 03, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599583
SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION
2y 5m to grant Granted Apr 14, 2026
Patent 12595263
PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR
2y 5m to grant Granted Apr 07, 2026
Patent 12590087
INHIBITING USP36
2y 5m to grant Granted Mar 31, 2026
Patent 12590080
NOVEL COMPOUNDS
2y 5m to grant Granted Mar 31, 2026
Patent 12583861
DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

6-7
Expected OA Rounds
68%
Grant Probability
96%
With Interview (+27.5%)
3y 8m
Median Time to Grant
High
PTA Risk
Based on 158 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month